Diagnostics

The biopharma company's strategic bid for non-dilutive funding could advance a first-in-class therapy for severe, untreated skin conditions.

A new partnership brings advanced, non-invasive Alzheimer's blood tests to community centers, aiming for mass early detection and reshaping diagnostics.

After a major turnaround, Genetix Biotherapeutics announces its first profitable quarter and plans to double production of its high-stakes gene therapies.

PenFed Foundation's latest accelerator cohort showcases veteran entrepreneurs tackling everything from national security to healthcare with military precision.

On its 13th anniversary, MOCO Connectors launched a new 8,000sqm facility in Zhongshan, scaling up custom connector production for global high-tech markets.

With 175 million lenses implanted, Alcon solidifies its market leadership. Discover the technology giving patients unprecedented freedom from glasses.

Neogen divests its pioneering genomics business for $160M to slash debt, while Zoetis bolsters its dominance in the animal health diagnostics market.

As MSA Awareness Month begins, a novel drug from Alterity Therapeutics shows significant promise in slowing the devastating and untreatable neurodegenerative disease.

As childhood nearsightedness soars, a new contact lens offers hope by not just correcting vision but actively slowing its progression in key global markets.

With star-studded advisory board, a new biotech firm aims to turn routine dental visits into a frontline defense against oral cancer.

In a radical pivot, diagnostics firm OpGen has become CapForce, an AI-powered investment bank targeting a $10B niche. Can it trade microbes for money?

The Michael J. Fox Foundation adds private equity and AI venture capital leaders to its board, signaling a strategic push to accelerate a cure for Parkinson's.

The stars join The Elizabeth Taylor AIDS Foundation to modernize laws from the '80s that criminalize HIV status, clashing with modern science.

A new partnership brings a high-speed digital pathology scanner to the U.S. for the first time, promising to revolutionize diagnostic speed and accuracy.

Over 140 health groups warn the EPA's 'flawed' fluoride review could reverse decades of public health gains, sparking a surge in childhood tooth decay.

Colorectal cancer is the #1 cancer killer for adults under 50. A new study reveals a shocking awareness gap that is fueling this growing public health crisis.

European biotech leader Hifas da Terra launches in the US, aiming to disrupt the mushroom supplement industry with its unique focus on clinical trials.

Fulgent Genetics reports revenue growth but faces a pivotal year with a major customer loss, betting its future on strategic acquisitions and a promising drug pipeline.

With Google's Rick Osterloh on its board, Dexcom signals a major push beyond diabetes into AI-powered wellness and the consumer wearables market.

The diagnostics firm topped revenue forecasts with explosive growth in core tests, navigating a net loss with a strategic pivot into new markets.